aytu biopharma inc - AYTU

AYTU

Close Chg Chg %
2.68 -0.03 -0.93%

Open Market

2.66

-0.03 (0.93%)

Volume: 30.21K

Last Updated:

Jan 13, 2026, 11:52 AM EDT

Company Overview: aytu biopharma inc - AYTU

AYTU Key Data

Open

$2.70

Day Range

2.61 - 2.70

52 Week Range

0.95 - 3.07

Market Cap

$27.30M

Shares Outstanding

10.19M

Public Float

9.25M

Beta

0.33

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.93

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

154.57K

 

AYTU Performance

1 Week
 
1.52%
 
1 Month
 
16.52%
 
3 Months
 
17.03%
 
1 Year
 
56.27%
 
5 Years
 
-98.20%
 

AYTU Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About aytu biopharma inc - AYTU

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Denver, CO.

AYTU At a Glance

Aytu Biopharma, Inc.
7900 East Union Avenue
Denver, Colorado 80237
Phone 1-720-437-6580 Revenue 66.38M
Industry Pharmaceuticals: Major Net Income -13,562,000.00
Sector Health Technology Employees 83
Fiscal Year-end 06 / 2026
View SEC Filings

AYTU Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.206
Price to Book Ratio 1.032
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 0.717
Enterprise Value to Sales 0.085
Total Debt to Enterprise Value 4.042

AYTU Efficiency

Revenue/Employee 799,783.133
Income Per Employee -163,397.59
Receivables Turnover 2.131
Total Asset Turnover 0.546

AYTU Liquidity

Current Ratio 1.256
Quick Ratio 1.074
Cash Ratio 0.491

AYTU Profitability

Gross Margin 63.493
Operating Margin 3.822
Pretax Margin -20.706
Net Margin -20.43
Return on Assets -11.659
Return on Equity -60.76
Return on Total Capital -33.845
Return on Invested Capital -40.511

AYTU Capital Structure

Total Debt to Total Equity 120.937
Total Debt to Total Capital 54.738
Total Debt to Total Assets 18.434
Long-Term Debt to Equity 62.638
Long-Term Debt to Total Capital 28.351
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Aytu Biopharma Inc - AYTU

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
96.67M 107.40M 81.00M 66.38M
Sales Growth
+47.29% +11.10% -24.58% -18.05%
Cost of Goods Sold (COGS) incl D&A
48.45M 45.55M 31.63M 24.23M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
10.25M 8.81M 8.27M 5.38M
Depreciation
2.45M 2.71M 1.72M 388.00K
Amortization of Intangibles
7.80M 6.10M 6.56M 4.99M
COGS Growth
+14.17% -5.98% -30.57% -23.38%
Gross Income
48.22M 61.84M 49.37M 42.15M
Gross Income Growth
+107.91% +28.26% -20.16% -14.64%
Gross Profit Margin
+49.88% +57.58% +60.95% +63.49%
2022 2023 2024 2025 5-year trend
SG&A Expense
84.32M 74.17M 52.26M 39.61M
Research & Development
14.44M 4.09M 2.79M 1.33M
Other SG&A
69.88M 70.08M 49.47M 38.28M
SGA Growth
+37.26% -12.03% -29.54% -24.21%
Other Operating Expense
- - - 2.00M
-
Unusual Expense
71.53M 4.74M 2.96M 10.36M
EBIT after Unusual Expense
(109.63M) (17.07M) (5.85M) (7.83M)
Non Operating Income/Expense
(651.00K) 14.00K (3.44M) (2.21M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 4.79M 3.70M
-
Interest Expense Growth
- - - -22.73%
-
Gross Interest Expense
- - 4.79M 3.70M
-
Interest Capitalized
- - - -
-
Pretax Income
(110.28M) (17.05M) (14.08M) (13.74M)
Pretax Income Growth
-90.04% +84.54% +17.45% +2.35%
Pretax Margin
-114.08% -15.88% -17.38% -20.71%
Income Tax
- (110.00K) 1.77M 437.00K
Income Tax - Current - Domestic
7.00K 126.00K 1.77M 437.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - (117.00K) (126.00K)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(110.17M) (17.05M) (15.84M) (14.18M)
Minority Interest Expense
- - - -
-
Net Income
(110.17M) (17.05M) (15.84M) (14.18M)
Net Income Growth
-89.01% +84.52% +7.08% +10.49%
Net Margin Growth
-113.97% -15.88% -19.56% -21.36%
Extraordinaries & Discontinued Operations
- - - 620.00K
-
Discontinued Operations
- - - 620.00K
-
Net Income After Extraordinaries
(110.17M) (17.05M) (15.84M) (13.56M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(110.17M) (17.05M) (15.84M) (13.56M)
EPS (Basic)
-74.954 -5.1052 -2.861 -2.1596
EPS (Basic) Growth
-7.67% +93.19% +43.96% +24.52%
Basic Shares Outstanding
1.47M 3.34M 5.54M 6.28M
EPS (Diluted)
-74.954 -5.1052 -2.861 -2.1596
EPS (Diluted) Growth
-7.67% +93.19% +43.96% +24.52%
Diluted Shares Outstanding
1.47M 3.34M 5.54M 6.28M
EBITDA
(27.85M) (3.51M) 5.38M 7.91M
EBITDA Growth
+8.80% +87.38% +253.19% +47.02%
EBITDA Margin
-28.81% -3.27% +6.65% +11.92%

Snapshot

Average Recommendation BUY Average Target Price 9.167
Number of Ratings 3 Current Quarters Estimate -0.247
FY Report Date 03 / 2026 Current Year's Estimate -0.657
Last Quarter’s Earnings -0.26 Median PE on CY Estimate N/A
Year Ago Earnings -2.26 Next Fiscal Year Estimate 0.023
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate -0.25 -0.15 -0.66 0.02
High Estimates -0.10 -0.10 -0.54 0.30
Low Estimate -0.38 -0.18 -0.86 -0.27
Coefficient of Variance -56.95 -30.12 -26.91 1,223.01

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Aytu Biopharma Inc - AYTU

Date Name Shares Transaction Value
Jun 11, 2025 Jarrett T. Disbrow Chief Business Officer 29,462 Open market or private purchase of non-derivative security Non-derivative transaction at $1.5 per share 44,193.00
Jun 11, 2025 Joshua R. Disbrow Chief Executive Officer 153,257 Open market or private purchase of non-derivative security Non-derivative transaction at $1.5 per share 229,885.50

Aytu Biopharma Inc in the News